Annual EBITDA:
-$8.71M-$4.48M(-106.01%)Summary
- As of today, AKBA annual EBITDA is -$8.71 million, with the most recent change of -$4.48 million (-106.01%) on December 31, 2024.
- During the last 3 years, AKBA annual EBITDA has risen by +$219.66 million (+96.19%).
- AKBA annual EBITDA is now -106.01% below its all-time high of -$4.23 million, reached on December 31, 2023.
Performance
AKBA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$14.40M+$577.00K(+4.17%)Summary
- As of today, AKBA quarterly EBITDA is $14.40 million, with the most recent change of +$577.00 thousand (+4.17%) on June 1, 2025.
- Over the past year, AKBA quarterly EBITDA has increased by +$13.72 million (+2002.92%).
- AKBA quarterly EBITDA is now -74.90% below its all-time high of $57.39 million, reached on June 30, 2022.
Performance
AKBA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$24.34M+$13.72M(+129.21%)Summary
- As of today, AKBA TTM EBITDA is $24.34 million, with the most recent change of +$13.72 million (+129.21%) on June 1, 2025.
- Over the past year, AKBA TTM EBITDA has increased by +$21.84 million (+873.52%).
- AKBA TTM EBITDA is now at all-time high.
Performance
AKBA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AKBA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -106.0% | +2002.9% | +873.5% |
| 3Y3 Years | +96.2% | -74.9% | +127.5% |
| 5Y5 Years | +96.5% | +129.6% | +110.3% |
AKBA EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -106.0% | +96.2% | at high | +135.3% | at high | +127.2% |
| 5Y | 5-Year | -106.0% | +96.5% | -74.9% | +118.5% | at high | +109.5% |
| All-Time | All-Time | -106.0% | +96.5% | -74.9% | +116.3% | at high | +109.5% |
AKBA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $14.40M(+4.2%) | $24.34M(+129.2%) |
| Mar 2025 | - | $13.83M(+1909.9%) | $10.62M(+221.9%) |
| Dec 2024 | -$8.71M(-106.0%) | -$764.00K(+75.6%) | -$8.71M(-408.0%) |
| Sep 2024 | - | -$3.13M(-557.1%) | $2.83M(+13.2%) |
| Jun 2024 | - | $685.00K(+112.4%) | $2.50M(+42.4%) |
| Mar 2024 | - | -$5.50M(-151.1%) | $1.76M(+119.9%) |
| Dec 2023 | -$4.23M(+85.7%) | $10.78M(+411.5%) | -$8.82M(+55.7%) |
| Sep 2023 | - | -$3.46M(-5764.4%) | -$19.90M(+65.2%) |
| Jun 2023 | - | -$59.00K(+99.6%) | -$57.24M(>-9900.0%) |
| Mar 2023 | - | -$16.08M(-5351.5%) | $214.00K(+100.6%) |
| Dec 2022 | -$29.57M(+87.1%) | -$295.00K(+99.3%) | -$33.33M(+62.7%) |
| Sep 2022 | - | -$40.80M(-171.1%) | -$89.34M(-1.1%) |
| Jun 2022 | - | $57.39M(+215.7%) | -$88.39M(+59.1%) |
| Mar 2022 | - | -$49.62M(+11.9%) | -$216.09M(+2.8%) |
| Dec 2021 | -$228.37M(-0.5%) | -$56.31M(-41.3%) | -$222.37M(+8.8%) |
| Sep 2021 | - | -$39.85M(+43.3%) | -$243.74M(+4.6%) |
| Jun 2021 | - | -$70.30M(-25.8%) | -$255.36M(-9.3%) |
| Mar 2021 | - | -$55.91M(+28.0%) | -$233.73M(-2.8%) |
| Dec 2020 | -$227.32M(+9.0%) | -$77.68M(-50.9%) | -$227.32M(+3.4%) |
| Sep 2020 | - | -$51.48M(-5.8%) | -$235.41M(-2.3%) |
| Jun 2020 | - | -$48.67M(+1.7%) | -$230.14M(+0.5%) |
| Mar 2020 | - | -$49.50M(+42.3%) | -$231.29M(+6.8%) |
| Dec 2019 | -$249.87M(-63.7%) | -$85.76M(-85.6%) | -$248.22M(+1.1%) |
| Sep 2019 | - | -$46.20M(+7.3%) | -$250.90M(-8.0%) |
| Jun 2019 | - | -$49.82M(+25.0%) | -$232.31M(-6.6%) |
| Mar 2019 | - | -$66.43M(+24.9%) | -$217.95M(-24.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$152.65M(-100.7%) | -$88.44M(-220.2%) | -$175.82M(-142.3%) |
| Sep 2018 | - | -$27.62M(+22.1%) | -$72.57M(-5.2%) |
| Jun 2018 | - | -$35.46M(-45.9%) | -$68.96M(-24.2%) |
| Mar 2018 | - | -$24.30M(-264.1%) | -$55.54M(+27.0%) |
| Dec 2017 | -$76.06M(+43.9%) | $14.81M(+161.7%) | -$76.08M(+40.9%) |
| Sep 2017 | - | -$24.01M(-9.0%) | -$128.80M(+8.6%) |
| Jun 2017 | - | -$22.04M(+50.9%) | -$140.88M(+9.1%) |
| Mar 2017 | - | -$44.84M(-18.2%) | -$154.99M(-14.2%) |
| Dec 2016 | -$135.66M(-122.0%) | -$37.92M(-5.1%) | -$135.76M(-15.2%) |
| Sep 2016 | - | -$36.09M(+0.1%) | -$117.83M(-16.3%) |
| Jun 2016 | - | -$36.14M(-41.1%) | -$101.31M(-33.4%) |
| Mar 2016 | - | -$25.61M(-28.2%) | -$75.92M(-24.2%) |
| Dec 2015 | -$61.12M(-63.2%) | -$19.98M(-2.1%) | -$61.12M(-18.2%) |
| Sep 2015 | - | -$19.57M(-81.9%) | -$51.72M(-24.0%) |
| Jun 2015 | - | -$10.76M(+0.4%) | -$41.72M(-7.5%) |
| Mar 2015 | - | -$10.81M(-2.0%) | -$38.80M(-3.3%) |
| Dec 2014 | -$37.45M(-135.1%) | -$10.59M(-10.7%) | -$37.57M(-13.2%) |
| Sep 2014 | - | -$9.57M(-22.3%) | -$33.18M(-20.0%) |
| Jun 2014 | - | -$7.83M(+18.3%) | -$27.64M(-20.5%) |
| Mar 2014 | - | -$9.58M(-54.5%) | -$22.93M(-43.9%) |
| Dec 2013 | -$15.93M(-86.9%) | -$6.20M(-53.7%) | -$15.93M(-37.4%) |
| Sep 2013 | - | -$4.03M(-29.3%) | -$11.60M(-53.3%) |
| Jun 2013 | - | -$3.12M(-21.1%) | -$7.56M(-70.3%) |
| Mar 2013 | - | -$2.58M(-38.2%) | -$4.44M(-138.2%) |
| Dec 2012 | -$8.52M(+45.0%) | - | - |
| Dec 2012 | - | -$1.86M | -$1.86M |
| Dec 2011 | -$15.50M | - | - |
FAQ
- What is Akebia Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Akebia Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Akebia Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Akebia Therapeutics, Inc.?
- What is Akebia Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Akebia Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of AKBA is -$8.71M
What is the all-time high annual EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high annual EBITDA is -$4.23M
What is Akebia Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, AKBA annual EBITDA has changed by -$4.48M (-106.01%)
What is Akebia Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of AKBA is $14.40M
What is the all-time high quarterly EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high quarterly EBITDA is $57.39M
What is Akebia Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, AKBA quarterly EBITDA has changed by +$13.72M (+2002.92%)
What is Akebia Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of AKBA is $24.34M
What is the all-time high TTM EBITDA for Akebia Therapeutics, Inc.?
Akebia Therapeutics, Inc. all-time high TTM EBITDA is $24.34M
What is Akebia Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, AKBA TTM EBITDA has changed by +$21.84M (+873.52%)